Difference between revisions of "Hainsworth JD, et al. Target Oncol. (2016) cited as Ref 633 in DOI: 10.1038/s41392-020-0110-5 (Q9896)"
Jump to navigation
Jump to search
(Added link to [sliswiki]: Hainsworth JD, et al. Target Oncol. (2016) cited as Ref 633 in DOI: 10.1038/s41392-020-0110-5, #quickstatements; #temporary_batch_1589988087154) |
(Created claim: Page(s) (P105): 643-653, #quickstatements; #temporary_batch_1590074839150) |
||||||||||||||
| (7 intermediate revisions by the same user not shown) | |||||||||||||||
| Property / First Author string | |||||||||||||||
| + | Hainsworth JD | ||||||||||||||
| Property / First Author string: Hainsworth JD / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / DOI Identifier | |||||||||||||||
| + | |||||||||||||||
| Property / DOI Identifier: 10.1007/s11523-016-0434-9 / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / PubMed ID | |||||||||||||||
| + | |||||||||||||||
| Property / PubMed ID: 27154357 / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / Publication Date | |||||||||||||||
| + | 2016
| ||||||||||||||
| Property / Publication Date: 2016 / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / Published In Name String | |||||||||||||||
| + | Target Oncol. | ||||||||||||||
| Property / Published In Name String: Target Oncol. / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / Volume | |||||||||||||||
| + | 11 | ||||||||||||||
| Property / Volume: 11 / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / title | |||||||||||||||
| + | A randomized open-label phase 2 study of the CXCR4 inhibitor LY2510924 in combination with sunitinib versus sunitinib alone in patients with metastatic renal cell carcinoma (RCC) (English) | ||||||||||||||
| Property / title: A randomized open-label phase 2 study of the CXCR4 inhibitor LY2510924 in combination with sunitinib versus sunitinib alone in patients with metastatic renal cell carcinoma (RCC) (English) / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / Page(s) | |||||||||||||||
| + | 643-653 | ||||||||||||||
| Property / Page(s): 643-653 / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
Latest revision as of 15:47, 21 May 2020
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Hainsworth JD, et al. Target Oncol. (2016) cited as Ref 633 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
Hainsworth JD
0 references
2016
0 references
Target Oncol.
0 references
11
0 references
A randomized open-label phase 2 study of the CXCR4 inhibitor LY2510924 in combination with sunitinib versus sunitinib alone in patients with metastatic renal cell carcinoma (RCC) (English)
0 references
643-653
0 references
